ASTRO 2022 | Genomic determinants of response to TMT for patients with muscle-invasive bladder cancer

Sophia Kamran, MD, Massachusetts General Hospital, Boston, MA, discusses the need for biomarkers to better select patients for trimodality therapy (TMT) for muscle-invasive bladder cancer. A recent trial investigated the use of DNA damage repair pathway genes as genomic determinants of response to TMT for muscle-invasive bladder cancer. It was found the ERCC2 gene is associated with an improved response to TMT. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.